Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system

Volume: 283, Pages: 69 - 78
Published: Apr 1, 2019
Abstract
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a liver secretory enzyme that controls plasma low-density lipoprotein cholesterol (LDL-C) levels through modulation of LDL receptor (LDLR). Inhibition of PCSK9 using monoclonal antibodies (mAbs) can efficiently lower plasma LDL-C. However, the relatively short half-life of mAbs necessitates frequent passive immunization, which is costly. These limitations can be circumvented by active...
Paper Details
Title
Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system
Published Date
Apr 1, 2019
Volume
283
Pages
69 - 78
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.